Table 3.

Univariate logistic regression analysis on the association of investigated variables with the occurrence of grade ≥3 hepatotoxicity during sotorasib treatment.

Variable	Univariate analysis	p-value
	OR (95% CI)
Sex (female versus male)	1.40 (0.51–3.82)	0.52
Age (≥65 years versus <65 years)	0.28 (0.11–0.76)	0.013
Liver metastasis (yes versus no)	0.25 (0.05–1.16)	0.076
Prior immune-related hepatotoxicity (yes versus no)	6.82 (1.28–36.48)	0.025
Anti-PD-(L)1 time on treatment (months, continuous scale)	1.01 (0.95–1.08)	0.71
Anti-PD-(L)1 interval (≤6 weeks versus >6 weeks)	18.85 (4.73–75.08)	<0.0001
Sotorasib time on treatment (months, continuous scale)	0.93 (0.84–1.03)	0.17
Median Ctrough sotorasib (≥122 ng/mL versus <122 ng/mL)	0.82 (0.23–2.85)	0.75
Median pembrolizumab concentration (≥11.4 μg/mL versus <11.4 μg/mL)	24.86 (5.69–108.63)	<0.0001

OR, odds ratio. CI, confidence interval. PD-(L)1, programmed death-(ligand) 1. C_trough, trough concentration.